Detail of "146426-40-6"

Reference

Synovial cell proliferation inhibitor

All Rights Reserved. Synovial cell proliferation inhibitor. Kosaka, Hitoshi; Miyasaka, Nobuyuki (National University Corporation Tokyo Medical and Dental University; Riken Corp., Japan). PCT Int. Appl. WO 2007010946 A1 25 Jan 2007, 31pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-JP314287 19 Jul 2006. PRIORITY: JP 2005-209111 19 Jul 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Disclosed is a synovial cell proliferation inhibitor which does not induce apoptosis or immunosuppression and can inhibit the proliferation of a synovial cell. 146426-40-6 which is the cas registry number of some chemical is mentioned. Also disclosed is a pharmaceutical compn. or therapeutic method which can treat a disease involving the synovial cell proliferation without reducing the resistance against a infection. A synovial cell proliferation inhibitor comprising at least one of flavopiridol (IUPAC name: alvocidib), which is a compd. of the structural formula (1), and a pharmaceutically acceptable salt thereof as an active ingredient; a pharmaceutical compn. comprising at least the synovial cell proliferation inhibitor; and a therapeutic method comprising at least administering the synovial cell proliferation inhibitor. .

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines

The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Robinson, William A.; Miller, Troy L.; Harrold, Elizabeth A.; Bemis, Lynne T.; Brady, Benjamin M. 146426-40-6 are also occured in this study.; Nelson, R. Peter (Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, CO, USA). Melanoma Research, 13(3), 231-238 (English) 2003 Lippincott Williams & Wilkins. CODEN: MREEEH. ISSN: 0960-8931. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Flavopiridol is the first cyclin-dependent kinase inhibitor to enter clin. trials. Flavopiridol has been shown to mimic, in part, the effect of the cell cycle control gene p16, which is frequently lost or mutated in malignant melanoma, making it an ideal candidate for targeted therapy in this disease. In these studies we investigated the effect of flavopiridol, at various concns., on the growth and gene expression of nine human melanoma cell lines with intact, absent or mutated p16. A cytostatic effect of flavopiridol on the growth of six melanoma cell lines with a mutated or non-expressed p16 (p16-) was seen at low concns. of flavopiridol (mean 50% inhibitory concn. [IC50] = 12.5 nM), while the three melanoma cell lines with intact p16 (p16+) required higher concns. (mean IC50 = 25 nM) to produce this effect. Apoptotic cell death increased with increasing concns. of flavopiridol in both p16- and p16+ cells. Exposure of cells to high flavopiridol concns. (>100 nM) resulted in decreased expression of genes downstream in the normal p16 cell cycle control pathway (Rb and E2F) and the anti-apoptotic gene BCL2. No change in BCL2 expression was found after exposure to IC50 concns. of flavopiridol. These data indicate that flavopiridol in low, clin. achievable concns. may have significant cytostatic effects, particularly in p16- melanoma cells, and may provide new mol.-based therapies for melanoma, particularly when combined with agents that target anti-apoptotic mechanisms. .